Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959036 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
A Phase 1 study of Active Rheumatoid Arthritis, sponsored by Ablynx, a Sanofi company.
- Completed
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT00959036: Completed Phase 1 study of Active Rheumatoid Arthritis, sponsored by Ablynx, a Sanofi company.
NCT00959036 is a Phase 1 study of Active Rheumatoid Arthritis that has completed, run by Ablynx, a Sanofi company. The registered enrollment target is 252 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (320% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00959036, a Phase 1 study of Active Rheumatoid Arthritis, has completed, sponsored by Ablynx, a Sanofi company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.
Conditions Studied
Interventions
- DRUG ATN-103
Study Locations (20)
Florida
- Investigational Site - Lake Mary
- Investigational Site - Ocala
- Investigational Site - Orlando
- Investigational Site - Port Orange
- Investigational Site - Vero Beach
Alabama
- Investigational Site - Birmingham
- Investigational Site - Huntsville
Arizona
- Investigational Site - Peoria
- Investigational Site - Scottsdale
California
- Investigational Site - Riverside
- Investigational Site - Upland
Connecticut
- Investigational Site - Bridgeport
Delaware
- Investigational Site - Newark
Idaho
- Investigational Site - Coeur d'Alene
Maryland
- Investigational Site - Frederick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
What the finished NCT00959036 record still lists
NCT00959036 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (320% higher).
The record links to 1 condition, with Active Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which ATN-103 is the first listed.
NCT00959036 names 20 study sites across 13 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00959036 about?
NCT00959036 is a clinical study titled "Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis". The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.
What is the current status of trial NCT00959036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2009-09. Estimated completion is 2011-01.
What conditions does trial NCT00959036 study?
This clinical trial studies the following conditions: Active Rheumatoid Arthritis.
What interventions are being tested in trial NCT00959036?
The interventions under investigation include: ATN-103 (DRUG).
Who is sponsoring clinical trial NCT00959036?
This trial is sponsored by Ablynx, a Sanofi company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00959036 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00959036's enrollment target sits among peer trials
252 169th of 2000 higher than 1,829 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia